You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

Drugs in MeSH Category Antibiotics, Antitubercular


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us RIFADIN rifampin CAPSULE;ORAL 050420-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Epic Pharma Llc RIFAMPIN rifampin CAPSULE;ORAL 064150-002 Jan 2, 1998 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Sanaluz SEROMYCIN cycloserine CAPSULE;ORAL 060593-001 Approved Prior to Jan 1, 1982 RX No Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Sanofi Aventis Us RIFADIN rifampin INJECTABLE;INJECTION 050627-001 May 25, 1989 AP RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Antibiotics, Antitubercular Market Analysis and Financial Projection

The global market for antitubercular antibiotics is undergoing significant transformation driven by evolving treatment paradigms, rising drug resistance, and strategic patent maneuvers. Below is an analysis of the market dynamics and patent landscape shaping this critical healthcare sector:


Market Dynamics

  1. Growth Projections:
    The anti-tuberculosis therapeutics market is projected to grow at a 6.2% CAGR from 2023–2028, while the drug-resistant TB treatment market is expected to reach $1.8 billion by 2033 (up from $1.1 billion in 2023) at a 4.9% CAGR[1][7][16]. Key drivers include:

    • Rising multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) cases, with 450,000 new MDR-TB cases reported in 2021[4].
    • Adoption of novel regimens (e.g., bedaquiline, delamanid) and repurposed drugs like clofazimine[6][7].
  2. Leading Drug Classes:

    • Isoniazid dominates first-line therapies due to its bactericidal efficacy and integration into shorter regimens[1][6].
    • Bedaquiline, critical for MDR-TB, accounts for 70% of MDR-TB regimen costs and has revolutionized outcomes[4][10].
    • Carbapenems paired with clavulanic acid are emerging for resistant strains[7].
  3. Regional Trends:

    • North America holds 37% market share, driven by robust R&D and high healthcare spending[7][16].
    • Africa and Asia face the highest TB burden but lag in access due to cost barriers[1][4].

Patent Landscape

  1. Key Players and Strategies:

    • Johnson & Johnson (bedaquiline): Holds secondary patents on formulations (expiring 2027) but agreed to non-enforcement in 134 LMICs in 2023, enabling generic competition[4][13].
    • Otsuka Pharmaceutical (delamanid): Filed patents covering combinations with isoniazid and formulations, expiring between 2023–2031[2][10].
    • Evergreening Tactics: Companies extend monopolies through secondary patents (e.g., salts, dosing regimens), delaying generics[10].
  2. Geographic Disparities:

    • High-Income Countries: Hold 70% of TB-related patents, with the U.S. (43%) and China (10%) leading[17].
    • LMICs: Only 30% of patents focus on diagnostics/vaccines, exacerbating treatment gaps[17].
  3. Breakthroughs and Access:

    • Viral vector vaccines: Adenovirus-based candidates in clinical trials show promise for TB prophylaxis[5].
    • Generic Expansion: Post-2023, bedaquiline generics are expected to reduce costs by 70% in LMICs[4][13].

Challenges and Innovations

  1. Access Barriers:

    • High drug prices (e.g., $1,200–$4,600 per MDR-TB course) limit LMIC access[10].
    • Complex regimens (e.g., 9–20 months) reduce patient adherence[6].
  2. Technological Advances:

    • Nanotechnology: Poly-lactide-glycolide nanoparticles enable sustained drug release, reducing dosing frequency[12].
    • Antimicrobial Peptides (AMPs): Emerging as alternatives with lower resistance risks[9].
  3. Policy Shifts:

    • Patent Pooling: The Stop TB Partnership’s Global Drug Facility (GDF) licenses generics for 96 countries, improving affordability[4][13].
    • Reformulated Regimens: Trials of rifapentine + isoniazid cut treatment from 9 to 3 weekly pills[1].

Future Outlook

  • Market Consolidation: Macleods, Lupin, and Pfizer are expanding portfolios for MDR-TB therapies[1][7].
  • Vaccine Development: 19 candidates are in clinical trials, with viral vectors and mRNA technologies leading[5][15].
  • Equity Focus: Advocacy groups push for compulsory licensing and R&D incentives in high-burden countries[17].

Highlight: "The market monopoly of TB drugs by high-income nations sustains obsolete technologies, but partnerships like GDF are countering this through generic licensing." [13][17]

Overall, the market is pivoting toward patient-centric regimens and equitable access, though patent barriers and resistance evolution remain critical hurdles.

References

  1. https://www.mordorintelligence.com/industry-reports/anti-tuberculosis-drugs-market
  2. https://unitaid.org/uploads/OPC-67683_Patent_Landscape.pdf
  3. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.00190/full
  4. https://www.science.org/content/article/major-drug-company-bends-battle-over-access-key-tb-treatment
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC11359462/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC10348322/
  7. https://market.us/report/drug-resistant-tuberculosis-treatment-market/
  8. https://unitaid.org/uploads/TMC_207_Patent_Landscape.pdf
  9. https://pubmed.ncbi.nlm.nih.gov/27235189/
  10. https://endtb.org/sites/default/files/2019-11/MSF_Brief_DR-TB_Drugs_UTM_2019.pdf
  11. https://www.science.gov/topicpages/c/complex+drug+regimens.html
  12. https://www.frontiersin.org/journals/drug-delivery/articles/10.3389/fddev.2023.1295815/full
  13. https://genevahealthfiles.substack.com/p/johnson-and-johnsons-patent-bedaquiline-tb
  14. https://www.treatmentactiongroup.org/wp-content/uploads/2021/11/hcv_tb_longacting_patent_trends.pdf
  15. https://pubmed.ncbi.nlm.nih.gov/34846976/
  16. https://media.market.us/drug-resistant-tuberculosis-market-news/
  17. https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/66618
Last updated: 2025-03-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.